Q2 2026 Holdings
Filed 2026-08-14 | 33 holdings | $1.7B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Relay Therapeutics Inc(RLAY) | COM | 75943R102 | $224.5M | 12,000,000 | 13.4% |
| Enliven Therapeutics Inc(ELVN) | COM | 29337E102 | $166.2M | 3,275,000 | 9.9% |
| Alkermes PLC(ALKS) | SHS | G01767105 | $157.2M | 3,000,000 | 9.4% |
| Cogent Biosciences Inc(COGT) | COM | 19240Q201 | $118.0M | 3,050,000 | 7.0% |
| Amylyx Pharmaceuticals Inc(AMLX) | COM | 03237H101 | $101.5M | 5,650,000 | 6.0% |
| Definium Therapeutics Inc(DFTX) | COM SHS | 24477V105 | $94.1M | 2,000,000 | 5.6% |
| Spyre Therapeutics Inc(SYRE) | COM NEW | 00773J202 | $75.2M | 846,786 | 4.5% |
| Alto Neuroscience Inc(ANRO) | COM SHS | 02157Q109 | $71.9M | 2,723,196 | 4.3% |
| Tango Therapeutics Inc(TNGX) | COM | 87583X109 | $70.3M | 2,250,000 | 4.2% |
| Eyepoint Inc(EYPT) | COM NEW | 30233G209 | $65.8M | 4,600,000 | 3.9% |
| Tyra Biosciences Inc(TYRA) | COM | 90240B106 | $59.9M | 1,875,000 | 3.6% |
| Damora Therapeutics Inc(GLTO) | COM NEW | 36322Q206 | $50.4M | 1,939,000 | 3.0% |
| Celldex Therapeutics Inc New(CLDX) | COM NEW | 15117B202 | $50.2M | 1,350,000 | 3.0% |
| Pharvaris N V(PHVS) | COM | N69605108 | $49.3M | 1,425,000 | 2.9% |
| LB Pharmaceuticals Inc(LBRX) | COM SHS | 50180M108 | $48.7M | 1,500,000 | 2.9% |
| Assembly Biosciences Inc(ASMB) | COM NEW | 045396207 | $38.9M | 1,415,000 | 2.3% |
| Editas Medicine Inc(EDIT) | COM | 28106W103 | $28.8M | 8,889,000 | 1.7% |
| Kymera Therapeutics Inc(KYMR) | COM | 501575104 | $28.7M | 250,000 | 1.7% |
| Perspective Therapeutics Inc(CATX) | COM NEW | 46489V302 | $21.6M | 6,336,782 | 1.3% |
| Century Therapeutics Inc(IPSC) | COM | 15673T100 | $21.3M | 8,695,652 | 1.3% |
| Zura BIO LTD(ZURA) | CLASS A ORD SHS | G9TY5A101 | $19.2M | 3,250,000 | 1.1% |
| Avalo Therapeutics Inc(AVTX) | COM NEW | 05338F306 | $18.8M | 1,018,319 | 1.1% |
| Inflarx NV(IFRX) | COM | N44821101 | $16.4M | 7,300,000 | 1.0% |
| An2 Therapeutics Inc(ANTX) | COM | 037326105 | $14.2M | 2,933,680 | 0.8% |
| Nuvalent Inc(NUVL) | COM | 670703107 | $12.4M | 100,000 | 0.7% |
| SAB Biotherapeutics Inc(SABS) | COM NEW | 78397T202 | $11.2M | 2,870,000 | 0.7% |
| Inhibikase Therapeutics Inc(IKT) | COM NEW | 45719W205 | $11.0M | 5,397,488 | 0.7% |
| Relmada Therapeutics Inc(RLMD) | COM | 75955J402 | $9.9M | 1,425,000 | 0.6% |
| Pepgen Inc(PEPG) | COM | 713317105 | $8.1M | 4,475,000 | 0.5% |
| Research Alliance Corp III | ORD SHS CL A | G75226103 | $5.4M | 500,000 | 0.3% |
| Helix Acquisition Corp III | USD CL A ORD SHS | G4444S107 | $5.3M | 500,000 | 0.3% |
| Leonabio Inc(LONA) | COM | 04746L203 | $4.3M | 464,398 | 0.3% |
| Vistagen Therapeutics Inc(VTGN) | COM | 92840H400 | $630.2K | 2,788,620 | 0.0% |